Tincture August 22, 2018
Grace Cordovano, PhD

2018 will be the year of data privacy, security, and transparency headlines.

The Facebook and Cambridge Analytica data scandal sparked a public awareness of the ethical standards and data use practices of companies with power. The most recent headlines of 23andMe’s partnership with GlaxoSmithKline generated outcries from many patients who are literally sick and tired of having their data taken advantage of and utilized for everyone else’s profit.

Patients asked:

“What other companies are anonymizing my protected health information (PHI) for commercial purposes?”

“Is my hospital, doctor, or pharmacy selling my anonymized data? How can I look that up?”

“If a company is using my data for profitable purposes, why am I not getting compensated for the access to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Cybersecurity, Govt Agencies, HIPAA, Patient / Consumer, Privacy / Security, Provider, Technology, Trends
Altman handpicked for Homeland Security's AI safety board
HHS Modifies HIPAA Privacy Rule to Shield Reproductive Health Information from Third Party Access
HHS final rule requires HIPAA compliance changes for reproductive health care information
HIPAA Privacy Protections for PHI related to Reproductive Health Care: The Final Rule and what Covered Entities and Business Associates need to Know
More FTC Privacy Action

Share This Article